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Abstract
Background: CCR2 plays a key role in regulating monocyte trafficking to sites of inflammation
and therefore has been the focus of much interest as a target for inflammatory disease.
Methods:  Here we examined the effects of CCR2 blockade with a potent small molecule
antagonist to determine the pharmacodynamic consequences on the peripheral blood monocyte
compartment in the context of acute and chronic inflammatory processes.
Results: We demonstrate that CCR2 antagonism in vivo led to a rapid decrease in the number of
circulating Ly6Chi monocytes and that this decrease was largely due to the CXCR4-dependent
sequestration of these cells in the bone marrow, providing pharmacological evidence for a
mechanism by which monocyte dynamics are regulated in vivo. CCR2 antagonism led to an
accumulation of circulating CCL2 and CCL7 levels in the blood, indicating a role for CCR2 in
regulating the levels of its ligands under homeostatic conditions. Finally, we show that the
pharmacodynamic changes due to CCR2 antagonism were apparent after chronic dosing in mouse
experimental autoimmune encephalomyelitis, a model in which CCR2 blockade demonstrated a
dramatic reduction in disease severity, manifest in a reduced accumulation of monocytes and other
cells in the CNS.
Conclusion: CCR2 antagonism in vivo has tractable pharmacodynamic effects that can be used to
align target engagement with biologic effects on disease activity.
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Background
CCR2 plays a central role in two monocyte migration
pathways. First, the constitutive recruitment of newly-
formed monocytes that express high levels of the marker
Ly6C (Ly6Chi) from the bone marrow to the peripheral
blood is directed by the constitutive production of the
CCR2 ligands monocyte chemotactic protein-1 (CCL2)
and monocyte chemotactic protein-3 (CCL7) [1,2]. Sec-
ond, the induced expression of CCR2 ligands at sites of
tissue injury and inflammation can lead to the recruit-
ment of monocytes directly to those tissues, where activa-
tion and differentiation into macrophage populations
occurs [3]. As a source of TNFα, IL-1β, IL-6 and other pro-
inflammatory mediators, macrophages are considered a
major contributor to chronic inflammatory processes
underlying diseases such as rheumatoid arthritis, multiple
sclerosis, and asthma [4,5]. CCR2 deficient (CCR2-/-) mice
exhibit reduced monocyte egress from the bone marrow
and trafficking to sites of experimentally-induced inflam-
mation, predicting that CCR2 blockade may be a viable
inflammatory disease target [1,2,6]. Consequently, much
interest has been placed on developing biologic and small
molecule antagonists of CCR2 - mediated monocyte
migration.
Very limited information has been published that
describes the effects of small molecule CCR2 antagonists
in vivo. In one report, INCB3344 was shown to be a potent
CCR2 antagonist, blocking binding of and migration
toward the ligand CCL2 in vitro [7]. This compound dem-
onstrated activity in a variety of in vivo inflammatory
models, such as thioglycollate-induced macrophage
recruitment to the peritoneal cavity, DTH responses, and
mouse experimental autoimmune encephalomyelitis
(EAE). However, no pharmacodynamic assay was
described in this report to provide a link between the
activity of the compound in vitro and the efficacy observed
in vivo and to provide a demonstration of target engage-
ment in vivo. Further, the potency of INCB3344 in chem-
otaxis assays performed in vitro, reflected in low IC50
values, may underestimate the EC50 of the compound in
vivo, where high levels of protein binding often substan-
tially reduce the potency of small molecule antagonists.
Here we characterized a potent CCR2 antagonist in vitro,
accounting for any reduction in potency due to protein
binding, and defined its pharmacodynamic effects on
monocyte homeostasis and migratory potential in vivo.
Further, we used pharmacodynamic measures to demon-
strate that the efficacy of MK0812 in mouse EAE was
linked to its pharmacodynamic modulation of CCR2
activity.
CXCR4 plays an important role in the retention of B cell
precursors and neutrophils in the bone marrow [8].
CXCR4 deficiency and small molecule CXCR4 antagonists
such as AMD3100 lead to a redistribution of neutrophils
from the bone marrow to the periphery [8,9]. However, to
date it has not been appreciated that CXCR4 regulates
monocyte trafficking or retention in the bone marrow. In
the course of these studies, we demonstrated that CXCR4
plays a role regulating monocyte redistribution to the
bone marrow when CCR2 function is blocked. These data
provide pharmacological evidence for a homeostatic bal-
ance between CXCR4-mediated retention of cells in the
bone marrow and CCR2-mediated egress of monocyte
into the peripheral blood.
Methods
Mice and reagents
BALB/cJ and C57BL/6J mice were obtained at 6-8 weeks of
age and housed under specific pathogen free conditions.
CCR2-/- mice were obtained from Deltagen, Inc. The mice
were maintained on a mixed C57BL/6 × 129Sv back-
ground. Homozygous wildtype CCR2+/+ and CCR2-/- lit-
termates were obtained from heterozygous mating pairs.
All animal studies were performed in compliance with the
Institutional Animal Care and Use Committee of the
Schering-Plough Research Institute. The CCR2 antagonist
MK0812 was synthesized according to the method
described in Patent US6812234 [10].
CCR2 membrane binding assay
The radio-ligand binding assay was done using scintilla-
tion proximity assay (SPA) technology as previously
described with some modifications [11]. Membranes (6
μg per assay point) from Ba/F3 cells transfected with
mouse CCR2), and wheat germ agglutinin-coated SPA
beads (450 μg per point; Amersham, Arlington Heights,
IL), were pre-incubated for 30 min at room temperature in
mouse plasma (C57BL/6 mouse, anticoagulant - sodium
citrate; Bioreclamation, Inc., Hicksville, NY) containing
10 mM HEPES, pH 7.2. Then, prebound to WGA-SPA
beads membranes were incubated at room temperature
for 6 h with the indicated concentrations of CCR2 antag-
onists (in mouse plasma, 1% DMSO, final) and 0.2 nM
125I-rhCCL2 in mouse plasma (S.A. 2200 Ci/mmol, Perk-
inElmer Life and Analytical Science, Boston, MA). Binding
was measured using a 1450 Microbeta Trilux counter
(Wallac, Gaithersburg, MD). Binding constants (IC50 and
slope) were calculated using GraphPad Prism software
(GraphPad Software, Inc., La Jolla CA).
CCR2 chemotaxis assay
Chemotaxis experiments were performed as described
previously with some modifications [11]. WeHi-274.1
cells (ATCC) were resuspended at 4 × 106 cells/ml in
mouse plasma (C57BL/6 mouse, anticoagulant - sodium
citrate; Bioreclamation, Inc.) containing 10 mM HEPES,Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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pH 7.2. Various concentrations of rmCCL2, diluted in
mouse plasma, were dispensed at 30 μl/well into disposa-
ble microchemotaxis plates (ChemoTx 101-5sp; Neuro
Probe, Gaithersburg, MD), which were then covered with
a filter. Cells were pre-incubated at 37°C with various
concentrations of MK0812 in a CO2 incubator for 30 min,
and then 25-μl cell aliquots were applied to each spot on
the filter. After incubation for 2 h at 37°C in a 5% CO2
incubator, the filters were removed. Migrated cells in the
bottom wells were transferred to a Microlite luminometer
plate (Thermo Fisher Scientific, Waltham, MA), and
assayed using CellTiter-Glo kit according to the manufac-
turer's instructions (Promega, Madison, WI). The area
under the curve (AUC) and inhibition constants (IC50 and
slope) were calculated using GraphPad Prism software.
Chemokine-induced monocyte migration in vivo
Recombinant mouse CCL2 and CCL3 (R & D Systems,
Minneapolis, MN) were dissolved in PBS and injected i.v.
in the lateral tail vein of BALB/c mice, CCR2-/- mice or
CCR2+/+ littermate controls. 30 min later, chemokine-
injected and control animals were euthanized, blood was
collected into EDTA-coated tubes. Plasma was collected
after centrifugation and frozen at -20°C until used for
measurements of CCL2, CCL7 or CXCL12 by ELISA (R &
D Systems). Where indicated, animals were dosed with
the CXCR4 antagonist AMD3100 (Sigma-Aldrich, St.
Louis, MO) subcutaneously 1 h prior to dosing with
MK0812 by oral gavage (p.o.). In all studies involving
MK0812, the compound was dosed as a solution in 0.4%
hydroxypropyl methylcellulose (MC) via oral gavage 1 h
prior to CCL2 or CCL3 administration.
Blood cell differential counts and flow cytometry
White blood cell differential counts to quantify total leu-
kocytes, lymphocytes, monocytes, neutrophils, basophils
and eosinophils were performed using mouse whole
blood collected into EDTA-coated tubes. Blood samples
were analyzed using the ADVIA 120 Hematology System
(Bayer HealthCare, LLC, Tarrytown, New York) according
to the manufacturer's instructions for analysis of mouse
blood.
To measure the number of CD11b+Ly6Chi monocytes,
blood was collected from euthanized mice into EDTA-
coated tubes. Blood was aliquoted into 96-well V-bottom
plates. To block nonspecific binding, normal rat serum
was added to a final concentration of 20% and incubated
for 10 min at room temperature. Blood was then incu-
bated with PerCP-Cy5.5-anti-CD11b, PE-antiLy6G, FITC-
anti-Ly6C and/or anti-CXCR4 antibodies or isotype con-
trols (BD Biosciences, Franklin Lakes, NJ) for 20 min at
RT. The cells were pelleted by centrifugation and erythro-
cytes were lysed using FACS Lysing Solution (BD Bio-
sciences) according to the manufacturer's instructions.
Cells were washed and analyzed on a FACS Calibur instru-
ment (BD Biosciences).
Experimental autoimmune encephalomyelitis
EAE was induced in C57BL/6 female mice at 10-12 weeks
of age. Mice were injected with 200 ng pertussis toxin
(Sigma-Aldrich, St. Louis, MO) i.v. on days 0 and 2. On
day 1, mice were immunized with 50 μg MOG35-55 pep-
tide (Princeton Biomolecules, Lanhorne, PA) emulsified
with 300 μg heat-killed Mycobacterium tuberculosis
(Difco, Detroit, MI) and injected in two 50 μl s.c. injec-
tions over the flanks. Beginning on day 5 post immuniza-
tion, animals were dosed with FTY720 (1 mg/kg, q.d.) or
MK0812 (10 or 30 mg/kg, b.i.d.) by oral gavage. Both
compounds were dissolved in 0.4% hydroxypropyl meth-
ylcellulose (MC). Control animals were dosed b.i.d with
MC. Animals were scored for clinical symptoms daily
using the following scoring system: 0, no signs of disease;
1, tail paralysis; 2, tail paralysis and hind limb weakness;
3, hind limb and tail paralysis; 4, hindlimb and forelimb
paralysis; 5, moribund or dead. Mice that reached a score
of 4 that did not improve within 24 h were euthanized
and assigned a score of 5 for humane reasons.
Analysis of central nervous system (CNS) infiltrates
To assess the infiltration of leukocytes into CNS tissues in
the EAE model, naïve mice or mice with EAE that had
been dosed with either MC (the vehicle) or MK0812 (30
mg/kg, b.i.d.) were euthanized and then perfused with 50
ml cold PBS containing 2% glucose and heparin (2.1 U/
ml). The spinal cord and brains were dissected and mono-
nuclear cells isolated using a Neural Tissue Dissociation
Kit (Papain) (Miltenyi Biotec, Inc., Auburn, CA) according
to the manufacturer's instructions. Isolated mononuclear
cells were then stained for flow cytometric analysis using
fluorochrome-conjugated anti-CD45, anti-CD11b, anti-
CD3, anti-Ly6G, anti-Ly6C antibodies (BD Biosciences),
washed and analyzed on a FACS Calibur instrument (BD
Biosciences).
Statistical analysis
Statistical comparisons between groups were performed
using Kruskal-Wallis ANOVA analyses using GraphPad
Prism software. P values < 0.05 were considered statisti-
cally significant.
Results
CCL2 induces monocyte migration in vivo
CCR2 plays an important role in regulating the homeo-
static recruitment of newly-formed monocytes from the
bone marrow to the peripheral blood [1,2]. To begin to
examine the mechanism behind this process, we first
assessed whether intravenous administration of a bolus of
CCL2 would lead to detectable changes in the circulating
pool of monocytes and other major blood leukocyte cellJournal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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populations. To this end, white blood cell differential
counts were performed to measure various cell types in
mouse whole blood 30 min after administration of CCL2
relative to control mouse blood. Under these conditions,
a three-fold increase in peripheral blood monocyte num-
bers was detected, with no significant change in the other
major cell populations, including neutrophils, lym-
phocytes, basophils or eosinophils (Figure 1). This selec-
tive effect on the monocyte population prompted us to
measure changes in the circulating monocyte pool with a
more specific methodology, whereby newly formed
monocytes can be detected by flow cytometry based on
expression of the Ly6C marker. We determined that a
bolus injection of CCL2 led to a five-fold increase in the
number of blood monocytes, as defined by lack of expres-
sion of the neutrophil marker Ly6G and expression of
CD11b and Ly6C (CD11b+Ly6Chi) (Figure 2A). A corre-
sponding reduction in cell number of the corresponding
population of cells in the bone marrow was detected in
the same animals, consistent with an increased recruit-
ment of monocytes from the bone marrow to the periph-
eral blood (Figure 2B). This effect was clearly mediated
through CCR2, since no such increase in peripheral blood
monocyte population was observed when CCL2 was
administered to CCR2-/- animals (Figure 2C).
The CCR2 antagonist MK0812 blocks CCR2 function in 
vitro
Having determined that this CCL2-induced monocyte
migration in vivo was CCR2 mediated, we used this system
to characterize the effects of the small molecule CCR2
antagonist MK0812, a highly potent and selective reagent
[12,13]. We first confirmed the potency of this compound
against CCR2 using a membrane binding assay. MK0812
inhibited the binding of 125I-labeled recombinant human
CCL2 to CCR2-containing mouse cell membranes with an
IC50 of 19 nM in the presence of 97% mouse plasma,
accounting for any shift in potency due to protein content
in vivo (Figure 3A). Similarly, MK0812 potently inhibited
CCL2-mediated chemotaxis of WEHI-274.1 cells with an
IC50 = 5 nM in the presence of 99% mouse plasma (Figure
3B, C). Having defined the high potency of this molecule
against mouse CCR2, we sought to characterize its effects
on monocyte migration in vivo.
Pharmacokinetic analysis of MK0812
We next evaluated the pharmacokinetic behavior of
MK0812 in vivo. Mice were dosed with MK0812 at 50 mg/
kg, p.o. and plasma was collected 1, 4, 8, or 16 h later to
determine the plasma exposure over time. The compound
displayed a T1/2 = 1.6 h, with Cmax = 27 μM and an AUC =
Administration of CCL2 in vivo leads to a selective increase in circulating monocytes Figure 1
Administration of CCL2 in vivo leads to a selective increase in circulating monocytes. BALB/c mice were injected 
with 300 ng CCL2 or PBS i.v. into the tail vein. 30 min later, blood was collected and analyzed for white blood cell counts using 
an ADVIA system to quantify (A) total leukocytes, (B) lymphocytes, (C) monocytes, (D) neutrophils, (E) basophils and (F) eosi-
nophils. ***p < 0.001 compared to PBS group. The data presented are the mean ± S.E.M. of six mice per group and are repre-
sentative of three independent experiments.Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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Administration of CCL2 in vivo leads to a CCR2-dependent increase in peripheral blood Ly6Chi monocytes Figure 2
Administration of CCL2 in vivo leads to a CCR2-dependent increase in peripheral blood Ly6Chi monocytes. 
BALB/c mice were injected with 300 ng CCL2 or PBS i.v. into the tail vein. 30 min later, blood (A) and bone marrow (B) were 
collected and stained for expression of CD11b and Ly6C. Neutrophils were excluded by gating on the Ly6G-negative popula-
tion. ***p < 0.001 and **p < 0.01 compared to PBS group. C, CD11b+Ly6Chi monocyte numbers were determined in the blood 
of CCR2+/+ and CCR2-/- mice 30 min after PBS or CCL2 injection. *p < 0.05 PBS WT versus PBS KO group and CCL2 WT ver-
sus CCL2 KO group. The data presented are the mean ± S.E.M. of six mice per group and are representative of three inde-
pendent experiments.Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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104 μM·h (data not shown). Thus, 16 h after a 50 mg/kg
dose, the plasma concentration of MK0812 was 50 nM, or
ten-fold higher than the IC50 for inhibition of chemotaxis
in the presence of 99% mouse plasma in vitro. Substan-
tially lower doses would therefore be required for com-
plete inhibition of CCR2 activity in acute in vivo assays of
2-3 h duration, as described below.
MK0812 inhibits binding to CCR2 and CCL2-mediated chemotaxis in vitro Figure 3
MK0812 inhibits binding to CCR2 and CCL2-mediated chemotaxis in vitro. A, Inhibition of binding of 125I-rhCCL2 to 
membranes from Ba/F3 cells transfected with mouse CCR2 was tested using the indicated concentrations of MK0812 or unla-
beled rmCCL2. B, The inhibition of WeHi-274.1 cell chemotaxis was tested with the indicated concentrations of MK0812. C, 
The area under the curves from the data depicted in (B) were calculated and plotted against the concentration of CCL2 to 
determine an IC50 = 5 nM for MK0812. The data presented are the mean ± S.E.M. and are representative of three independent 
experiments.Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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Pharmacodynamic effects of the CCR2 antagonist 
MK0812
We next sought to assess the effect of MK0812 on CCR2-
dependent monocyte migration in vivo. As shown above,
intravenous injection of a 300 ng bolus of CCL2 led to a
clear increase in the number of blood CD11b+Ly6Chi
monocytes (Figure 4A). Oral administration of MK0812 1
h prior to the CCL2 challenge dose-dependently and com-
pletely inhibited this response. We determined the con-
centration of MK0812 present in the plasma at the time of
blood collection in order to define the pharmacokinetic -
pharmacodynamic relationship for this compound. We
observed a linear relationship between the administered
dose of MK0812 and the levels of the compound present
in the plasma. The most complete inhibition of the CCL2-
driven increase in monocyte number was observed at
doses that achieved plasma concentrations of MK0812
above the in vitro IC50 for this compound (Figure 4B).
Thus, the in vivo effects of MK0812 align well with the pre-
dicted potency based on the in vitro characterization of the
compound.
In the course of this experiment, we noted that the circu-
lating pool of CD11b+Ly6Chi monocytes decreased in ani-
mals as a consequence of dosing with MK0812 (Figure
4A). This finding is likely a reflection of the role of CCR2
in the homeostatic process of monocyte recruitment from
the bone marrow to the peripheral blood. In order to
extend the characterization of the effects of CCR2 antago-
nist administration, we performed additional analyses of
the blood from animals dosed with MK0812. As shown
above, oral administration of MK0812 led to a dose-
dependent reduction of up to 75% of circulating
CD11b+Ly6Chi monocytes (Figure 5A). In addition, the
levels of CCL2 and CCL7, two important ligands for CCR2
implicated in recruitment from the bone marrow, were
significantly elevated in mice dosed with MK0812 (Figure
5B, C). This effect was selective for CCR2 ligands, since no
change was observed in plasma levels of a selection of
other chemokines, including CCL3, CCL4, CXCL1,
CXCL2, and CXCL12 (data not shown). Further, we
repeated these studies using the structurally distinct CCR2
antagonist INCB3344 and observed similar pharmacody-
namic effects on blood Ly6Chi monocyte number and cir-
culating CCL2 and CCL7 levels (data not shown). In
addition, elevated levels of CCL2 and CCL7, but not other
chemokines, was observed in the plasma of CCR2-/- mice
relative to CCR2+/+  littermates, indicating that these
changes in CCR2 ligand levels were general phenomena
of CCR2 antagonism and absence of CCR2 expression
(data not shown).
While CCR2 antagonism in vivo rendered CD11b+Ly6Chi
monocytes non-responsive to CCL2, we sought to deter-
mine if this monocyte population remained responsive to
other chemotactic signals. We determined that intrave-
nous administration of the CCR1 ligand macrophage
inflammatory protein-1α (CCL3) into naive mice caused
a recruitment of monocytes into the peripheral blood sim-
ilar to that observed with CCL2 (Figure 5D). This result
suggests that both CCR1 and CCR2 ligands can mediate
the direct recruitment of monocytes from the bone mar-
row to the peripheral blood. Notably, while administra-
tion of MK0812 paralyzed the ability of this monocyte
population to response to CCL2, responsiveness to CCL3
remained intact, such that CCL3 induced a 2.5-3-fold
increase in Ly6Chi monocyte number both in the presence
and absence of MK0812 (Figure 5D). As discussed later,
this finding may have important implications for the use
of CCR2 antagonists to treat human disease. Finally,
administration of MK0812 to mice caused a selective
decrease in the circulating monocyte population, as white
blood cell counts for the other major blood cell popula-
tions remained unchanged (Figure 5E).
Role for CXCR4 in the modulation of peripheral monocyte 
number by MK0812
The reduction in circulating CD11b+Ly6Chi monocytes
that occurs after CCR2 antagonist treatment could be due
to a recycling of monocytes from the blood back to the
bone marrow or could simply reflect the further migration
of monocytes into tissues where differentiation to macro-
phage and dendritic cell subsets occurs. One potential
recycling mechanism could involve the stromal cell-
derived factor-1 (CXCL12) - mediated retention of leuko-
cytes mediated through CXCR4 [8,14]. We first examined
the expression of CXCR4 on Ly6G-CD11b+Ly6Chi mono-
cytes in the blood and bone marrow of naïve mice. While
CXCR4 was clearly detectable on 34% of bone marrow
Ly6Chi monocytes, we did not detect expression on the
corresponding blood monocyte population (Figure 6A).
To assess the role of CXCR4 on the decrease in blood
monocytes upon CCR2 antagonism, we treated animals
with the selective CXCR4 antagonist AMD3100 prior to
administration of MK0812. As shown above, in animals
pretreated with vehicle alone, MK0812 caused a signifi-
cant decrease in CD11b+Ly6Chi blood monocytes (Figure
6B). Pretreatment with AMD3100 significantly and dose-
dependently counteracted the effect of the CCR2 antago-
nist. These data suggest that the reduced peripheral mono-
cyte number in CCR2 antagonist treatment is largely due
to recycling of this population back into the bone marrow
via CXCR4. In all animals dosed with the CCR2 antago-
nist, there was a clear elevation in plasma CCL2 levels,
suggestive of comparable CCR2 receptor coverage in all
groups (Figure 6B). An elevation in plasma CXCL12 levels
was detected in animals treated with the highest dose of
AMD3100, consistent with substantial coverage of CXCR4
at the 10 mg/kg dose (Figure 6B). Notably, this dose ofJournal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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MK0812 inhibits CCL2-mediated monocyte migration in vivo Figure 4
MK0812 inhibits CCL2-mediated monocyte migration in vivo. A, BALB/c mice were administered the indicated dosage 
of vehicle (MC) or MK0812 by oral gavage. 1 h later, the mice were injected with PBS or 300 ng CCL2 i.v. 30 min later, periph-
eral blood CD11b+Ly6Chi monocyte numbers were determined as in Figure 2. B, The plasma concentrations of MK0812 were 
determined from the animals used in (A) and plotted versus the dosage of MK0812 administered. The IC50 for inhibition of 
CCL-2 mediated chemotaxis (see Figure 3) is indicated by a dashed line. The data presented are the mean ± S.E.M. of six mice 
per group and are representative of three independent experiments. **p < 0.01 compared to MC/CCL2 group.Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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Pharmacodynamic effects of MK0812 in vivo Figure 5
Pharmacodynamic effects of MK0812 in vivo. BALB/c mice were administered the indicated dosage of vehicle (MC) or 
MK0812 by oral gavage. 2 h later, peripheral blood CD11b+Ly6Chi monocyte numbers were determined as in Figure 2 (A) and 
plasma concentrations of CCL2 (B) and CCL7 (C) were determined. ***p < 0.001 and **p < 0.01 compared to MC group. D, 
The effect of MK0812 (3 mg/kg, p.o.) or vehicle (MC) on CCL2 and CCL3 mediated changes in CD11b+Ly6Chi monocyte num-
bers were evaluated as in Figure 4. **p < 0.01 compared to PBS group. E, BALB/c mice were dosed with vehicle (MC) or 
MK0812 (30 mg/kg, p.o.) and 2 h later, blood was collected and analyzed for white blood cell counts using an ADVIA system to 
quantify total leukocytes, lymphocytes, monocytes, neutrophils, basophils and eosinophils. *p < 0.05 compared to MC group. 
The data presented are the mean ± S.E.M. of six mice per group and are representative of three independent experiments.Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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The pharmacodynamic effect of MK0812 on monocytes is mediated by CXCR4 Figure 6
The pharmacodynamic effect of MK0812 on monocytes is mediated by CXCR4. A, Blood and bone marrow were 
isolated from naïve BALB/c mice and stained for expression of CD11b, Ly6G, Ly6C and CXCR4. Neutrophils were excluded 
by gating on the Ly6G- population and monocytes were gated upon based on CD11b+Ly6Chi expression. The expression of 
CXCR4 on the gated CD11b+Ly6Chi monocytes is indicated. B, BALB/c mice were administered the indicated dosage of vehicle 
(MC) or AMD3100 s.c. 1 h later, mice were dosed p.o. with MK0812 or vehicle. 30 min later, peripheral blood CD11b+Ly6Chi 
monocyte numbers were determined as in Figure 2. Plasma concentrations of CCL2 and CXCL12 were determined from the 
same mice. ***p < 0.001, *p < 0.05 compared to the Vehicle group. C, The effect of AMD3100 was assessed on Ly6G-
CD11b+Ly6Chi monocytes and Ly6G+Ly6C+ neutrophils. **p < 0.01 as shown. The data presented are the mean ± S.E.M. of six 
mice per group and are representative of three independent experiments.Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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AMD3100 also had the greatest impact on monocyte lev-
els in the plasma.
To rule out the possibility that CXCR4 antagonism alone
could cause an elevation in peripheral monocyte number
independent of CCR2 antagonism, we examined whether
mice dosed with AMD3100 alone affected peripheral
monocyte and neutrophil populations. At the highest
dose tolerable to mice, 30 mg/kg, AMD3100 had only a
modest effect on the peripheral Ly6Chi monocyte number
relative to vehicle treated animals, while a clear reversal of
the effects of MK0812 were again observed (Figure 6C). As
expected, CXCR4 antagonism alone did lead to a substan-
tial increase in peripheral blood Ly6G+Ly6C+ neutrophils,
an effect that was observed to be independent of CCR2
antagonism (Figure 6C). Thus, CXCR4-mediated reten-
tion of neutrophils in the bone marrow is a mechanism to
limit neutrophil egress from the bone marrow under
homeostatic conditions.
The CCR2 antagonist MK0812 blocks EAE
The results presented above describe the acute effects of
CCR2 antagonism in vivo. We sought to determine
whether these findings could be extended to situations of
chronic CCR2 antagonism in the context of disease mod-
ification. We therefore tested the effect of MK0812 in
mouse experimental autoimmune encephalomyelitis
(EAE), a model in which CCR2+Ly6Chi monocytes play a
crucial role in disease pathology [15]. C57BL/6 mice were
immunized with myelin oligodendrocyte glycoprotein
peptide residues 35-55 (MOG35-55). Five days after immu-
nization, before clinical symptoms were evident, animals
were divided into groups and dosed with either vehicle or
MK0812 (10 or 30 mg/kg, b.i.d., p.o.). As a positive con-
trol, one group of animals was dosed with the sphingo-
sine-1 phosphate receptor agonist FTY720 (1 mg/kg, q.d.,
p.o.), a therapeutic that has been shown to be efficacious
in EAE models [16]. Clinical scores were assigned each
day using the scoring system described in the Methods
until day 21, when the study was terminated. As expected,
FTY720 significantly and completely inhibited disease
progression (Figure 7A, B). Strikingly, both doses of
MK0812 almost completely blocked disease progression.
There was moderate dose dependence evident in the data
expressed as mean daily clinical scores or as the area under
the curve (AUC) of the disease scores over the course of
the experiment (Figure 7A and 7B, respectively).
At the termination of the study, we assessed the number
of CD11b+Ly6Chi  monocytes in the peripheral blood.
Notably, there was a dose-dependent reduction in this
monocyte population in animals treated with MK0812. In
contrast, animals treated with FTY720 showed an elevated
monocyte number that likely is due to a corresponding
reduction in number of circulating lymphocytes in these
animals. In addition, MK0812-treated animals had ele-
vated levels of CCL2 in the plasma (Figure 7D). This effect
was specific to the groups treated with a CCR2 antagonist
as there was no change in plasma CCL2 levels in mice
dosed with FTY720. Therefore, the pharmacodynamic
effects of CCR2 antagonism observed after acute treat-
ment extend to chronic dosing regimens and provide
biomarkers of CCR2 antagonism in the context of the EAE
disease model. As such, these biomarkers may be of utility
to gauge target engagement in the context of human clin-
ical trials with CCR2 antagonists.
The reduction in EAE disease severity as a result of
MK0812 treatment may relate to the inhibition of recruit-
ment of Ly6Chi monocytes to the CNS, where activation
and differentiation to the macrophage lineage could con-
tribute to disease pathology. To assess the effect of
MK0812 on leukocyte accumulation in the CNS, we iso-
lated cells from the spinal cord and brain tissues of mice
immunized with MOG35-55  and dosed with MC or
MK0812 (30 mg/kg, b.i.d., p.o.) as described above. Flow
cytometric analyses of the isolated cells indicated that ele-
vations in CD11b+Ly6Chi  monocytes, CD11b+CD45hi
macrophages, CD11b+CD45lo microglia, CD45+CD3+ T
lymphocytes, and CD45+Ly6G+ neutrophils were evident
in isolates from mice with EAE compared to naïve mice
(Figure 8). Mice treated with MK0812 had significantly
decreased levels of both Ly6Chi monocytes as well as all
other leukocyte populations that were analyzed. There-
fore, the reduction in EAE clinical disease severity follow-
ing MK0812 treatment is consistent with a reduced
accumulation of CCR2-expressing Ly6Chi monocytes and/
or other cells.
Discussion
For many years, it has been appreciated that monocytes
are a highly dynamic population. In the mouse, over the
span of 24 h, on the order of a million monocytes transit
from the bone marrow to the peripheral blood, half of
which migrate further into tissues, where differentiation
to various macrophage and dendritic cell populations can
occur [17]. Over the past several years, it has been appre-
ciated that CCR2 plays an important role in regulating
monocyte traffic from the bone marrow to the peripheral
blood, providing a molecular basis for the continuous
supply of newly formed monocytes. Here we demon-
strated that blockade of CCR2 function with a small mol-
ecule antagonist leads to a rapid decline in the number of
circulating newly formed CD11b+Ly6Chi  monocytes.
These data demonstrate the highly dynamic nature of
monocyte traffic under normal homeostatic conditions.
Further, we show that CCL2 and CCL7 are present at
detectable levels in normal mouse plasma. While the con-
stitutive source for these chemokines has not been
defined, it allows the formation of a gradient of the chem-Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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okine that directs monocyte traffic from the bone marrow
to the blood. In the presence of a CCR2 antagonist in vivo,
the levels of circulating CCL2 and CCL7 increased signifi-
cantly, indicating that the continuous consumption of
these factors, through interactions with CCR2, regulate
their levels in the plasma. Similarly, the CXCR4 antago-
nist AMD3100 caused an increase in the basal levels of
CXCL12 in the plasma, indicating a similar role for this
receptor in clearance of its ligands. It appears to be a gen-
eral phenomenon that chemokine receptor antagonism
recapitulates the observation that CCR2, CXCR2, CXCR3
and CX3CR1 knockout mice each have elevated levels of
their respective ligands [18].
The rapid decrease in monocyte number in the presence
of a CCR2 antagonist prompted us to explore the mecha-
nism behind this decrease. Since CXCL12-CXCR4 interac-
tions are an important mechanism by which leukocyte
populations are retained in the bone marrow, we exam-
ined whether a selective CXCR4 antagonist would impact
the CCR2 antagonist effect on monocyte number. Our
data indicate that blockade of CXCR4 greatly abrogated
Chronic MK0812 treatment inhibits EAE accompanied by pharmacodynamic effects Figure 7
Chronic MK0812 treatment inhibits EAE accompanied by pharmacodynamic effects. A, Effect of MK0812 (10 mg/
kg, b.i.d., p.o.) and FTY720 (1 mg/kg. q.d., p.o.) on EAE severity in C57BL/6J mice. Drug dosing was initiated at d5 after immuni-
zation with MOG35-55 peptide in CFA. B, The areas under the curve from the data depicted in (A) were calculated. C, Blood 
CD11b+Ly6Chi monocyte numbers (C) and the plasma concentration of CCL2 (D) were determined from the mice at d21. 
***p < 0.001, **p < 0.01, *p < 0.05 compared to MC group. The data presented are the mean ± S.E.M. of twnenty-five mice per 
group and are representative of three independent experiments.Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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Chronic MK0812 treatment inhibits the accumulation of monocytes, macrophages and other leukocyte populations in the CNS Figure 8
Chronic MK0812 treatment inhibits the accumulation of monocytes, macrophages and other leukocyte popu-
lations in the CNS. A, Leukocytes were isolated from naïve mice or mice immunized with MOG35-55 and dosed with 
MK0812 (30 mg/kg, b.i.d., p.o.) or MC as in Figure 7. Leukocyte isolations were performed between days 14-21, when clinical 
disease was evident in the EAE/MC group. The number of monocytes, macrophages, microglia, T lymphocytes and neutrophils 
were calculated based on flow cytometric analyses using the indicated combinations of cell surface markers. Cell numbers indi-
cated are total cells per mouse. **p < 0.01 and *p < 0.05 compared to MC group. The data presented are the mean ± S.E.M. of 
five mice per group and are representative of two independent experiments.Journal of Inflammation 2009, 6:32 http://www.journal-inflammation.com/content/6/1/32
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the decrease in monocyte number induced by a CCR2
antagonist, and is the primary if not only, explanation for
this decrease. These data suggest the presence of a balance
between CXCR4-mediated retention of monocytes in the
marrow and CCR2-mediated export of these cells to the
periphery. The balance between CXCL12 and CCL2 levels
therefore appears to comprise a rheostat that regulates
monocyte egress from the bone marrow. We also demon-
strated that this balance can be shifted in favor of
enhanced monocyte egress in that an i.v. injection of a
bolus of CCL2 led to a rapid increase in CD11b+Ly6Chi
monocytes in the peripheral blood. Likewise, in the con-
text of inflammation where CCR2 ligands are produced, a
direct recruitment of monocytes from the bone marrow
into the blood and eventually to inflamed tissues is con-
ceivable. In these studies, we demonstrated the expression
of CXCR4 on bone marrow Ly6Chi monocytes, but did not
detect expression of this receptor on blood monocytes.
These data suggest that CXCR4 expression is highly
dynamic and may be down-regulated rapidly around the
time of egress from the bone marrow to peripheral blood.
Since CXCR4 appears to play a role in blood monocyte
trafficking when CCR2 is antagonized, CXCR4 expression
may be highly dynamic in this monocyte population,
such that CXCR4 expression is restored upon CCR2 antag-
onism.
Notably, paralysis of CCR2 with an antagonist did not
affect the ability of monocytes to respond to CCR1-
directed recruitment to the blood. This finding is consist-
ent with in vitro chemotaxis data that indicate that selec-
tive chemokine receptor antagonism does not affect the
ability of cells to migrate in response to other receptors
present on the same cell. These data indicate that CCR2
blockade does not preclude the ability of monocytes to be
recruited from the bone marrow via other receptors. One
implication of this result is that CCR2 antagonists alone
may be inadequate to block inflammatory conditions in
which production of ligands for multiple monocyte
chemokine receptors occurs. This redundancy has been
appreciated for some time and may explain the lack of
clinical efficacy of selective biologic and small molecule
CCR2 antagonists in diseases such as rheumatoid arthritis
[19,20]. On the other hand, some degree of redundancy
may be viewed as sparing - complete blockade of all ave-
nues of monocytes recruitment to tissues might be unac-
ceptable in terms of host defense and
immunosurveillance. Finding the right balance between
these two issues remains a challenge for the development
of chemokine receptor antagonists suitable for clinical
use.
Finally, we demonstrate clear efficacy of a potent CCR2
antagonist in EAE. These data extend previous observa-
tions with another small molecule antagonist, INCB-
3344, in this model and are consistent with the decreased
susceptibility of CCR2-/- mice to EAE [6,7]. Two pharma-
codynamic markers of CCR2 antagonism, a decrease in
peripheral blood CD11b+Ly6Chi monocytes and an eleva-
tion in plasma CCL2, were evident after chronic dosing
with MK0812 in the EAE model. These pharmacodynamic
markers provide tools that could be applied to clinical tri-
als to monitor CCR2 receptor engagement in future stud-
ies.
Consistent with the potent inhibition of Ly6Chi monocyte
trafficking in vitro and in acute in vivo inflammatory set-
tings, we observed a dramatic reduction in Ly6Chi mono-
cytes in CNS tissues from MOG35-55 immunized mice
treated with MK0812. The inhibition of monocyte recruit-
ment in this disease setting would likely have the direct
effect of limiting the accumulation of differentiated mac-
rophage lineage cells capable of proinflammatory media-
tor production as well as secondary effects on recruitment
of other cell lineages, including T lymphocytes and neu-
trophils, all of which were found in reduced numbers in
the CNS of mice treated with MK0812. It should be noted
that the impact of CCR2 antagonism by MK0812 in the
EAE model may not be entirely due to inhibition of
monocyte trafficking. Inhibition of other CCR2-depend-
ent processes (e.g. through effects on the subset of T lym-
phocytes that express CCR2) may contribute to the
efficacy that was observed in this disease setting. The rela-
tive contribution of various CCR2-expressing cell popula-
tions to the EAE disease process thus remains an
important unresolved question. Irrespective of the contri-
bution of monocytes to the effect of MK0812 in this
model, our data support the utility of monitoring mono-
cyte numbers and CCR2 ligands in the peripheral blood as
pharmacodynamic measures of CCR2 antagonism in vivo.
Conclusion
Here we demonstrated that CCR2 antagonism in vivo
results in a reduction in the circulating Ly6Chi monocyte
population and an increase in circulating levels of the
CCR2 ligands CCL2 and CCL7. We further demonstrated
that CXCR4 plays a major role in the alteration in circulat-
ing monocytes under these conditions, revealing a role for
CXCR4 and CCR2 in regulating monocyte homeostasis.
Finally, the pharmacodynamic changes resulting from
CCR2 antagonism in acute settings translated to situations
of chronic drug treatment and provide potential biomark-
ers applicable to clinical trials with CCR2 antagonists in
human populations.
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